Skip to main content

Kiora Pharmaceuticals Inc

KPRX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001372514

No open-market purchases or sales by Kiora Pharmaceuticals Inc insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $2.91M in total; no superinvestor holds it.

Other share classesKPHMW

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Kiora Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Kiora Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Kiora Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
Lane Keith J.Other: EVP, Clinical and Regulatory–Sep 17, 20261
Tosca MelissaCFO26,064Jul 2, 20263
Strem Brian M.President and CEO58,823Jul 2, 20264
Tyle PraveenDirector5,014Jun 12, 20261
Walters-Hoffert LisaDirector1,250Jun 12, 20261
Hollander DavidDirector–Jun 12, 20261
Shapiro AronDirector3,000IndirectJun 12, 20261
Stengone Carmine N.Director1,250Jun 12, 20261
Parsons ErinDirector5,260IndirectJun 12, 20261
Daniels Eric JosephChief Development Officer31,741Apr 2, 20263
Gayron Kenneth LDirector–Oct 3, 20230
Chaney Paul GDirector–Mar 7, 20230
Romano SarahChief Financial Officer22,746Feb 11, 20220
From StephenExecutive Chairman67,693Jan 6, 20220
Mann BrendaVP of Research & Development15,136Nov 3, 20210
Manzo Michael P.VP of Engineering15,378Aug 4, 20210
Armistice Capital, LLC10% Owner785,000IndirectAug 3, 20210
Armistice Capital Master Fund Ltd.10% Owner785,000IndirectAug 3, 20210
Boyd Steven10% Owner785,000IndirectAug 3, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 12, 2024 (view filing)Sep 111 dayStengone Carmine N.DirectorPPurchase+1.25K$3.68+$4.60KNew position1.25K after
Sep 11, 2024 (view filing)Sep 101 dayShapiro AronDirectorPPurchase+3.00K$3.60+$10.8KNew position3.00K after
Aug 20, 2024 (view filing)Aug 191 dayWalters-Hoffert LisaDirectorPPurchase+1.25K$3.86+$4.83KNew position1.25K after
Aug 19, 2024 (view filing)Aug 19Same dayTyle PraveenDirectorPPurchase+5.00K$3.96+$19.8K+35,714.3%5.01K after
Aug 15, 2024 (view filing)Aug 141 dayTosca MelissaCFOPPurchase+2.00K$3.21+$6.42K+17.2%13.6K after
Jun 14, 2024 (view filing)Jun 14Same dayTosca MelissaEVP FinancePPurchase+100$5.25+$525+2.6%3.98K after
Jun 14, 2024 (view filing)Jun 14Same dayDaniels Eric JosephChief Development OfficerPPurchase+1.43K$5.29+$7.57K+14.6%11.2K after
Jun 13, 2024 (view filing)Jun 13Same dayParsons ErinDirectorPPurchase+5.26K$4.88+$25.7KNew position5.26K after
Jun 13, 2024 (view filing)Jun 13Same dayStrem Brian M.President and CEOPPurchase+3.00K$5.00+$15.0K+26.0%14.5K after
Nov 22, 2021 (view filing)Nov 184 daysStrem Brian M.President and CEOPPurchase+17.9K$1.41+$25.2K+187.6%27.4K after
Aug 3, 2021 (view filing)5:09 PM ETJul 30-Aug 24 daysArmistice Capital, LLC and 2 others10% OwnerSSale−261.0K$2.48−$646.6K−24.9%785.0K after2 lots
Jul 29, 2021 (view filing)7:59 PM ETJul 27-292 daysArmistice Capital, LLC and 2 othersDirector, 10% OwnerSSale−3.15M$4.61−$14.5M−75.1%1.05M after7 lots